{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:09:16Z","timestamp":1791727756129,"version":"4.3.4"},"reference-count":221,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With recent advances, chimeric antigen receptor (CAR) immunotherapy has become a promising modality for patients with refractory cancer diseases. The successful results of CAR T cell therapy in relapsed and refractory B-cell malignancies shifted the paradigm of cancer immunotherapy by awakening the scientific, clinical, and commercial interest in translating this technology for the treatment of solid cancers. This review elaborates on fundamental principles of CAR T cell therapy (development of CAR construct, challenges of CAR T cell therapy) and its application on solid tumors as well as CAR T cell therapy potential in the field of neuro-oncology. Glioblastoma (GBM) is identified as one of the most challenging solid tumors with a permissive immunological milieu and dismal prognosis. Standard multimodal treatment using maximal safe resection, radiochemotherapy, and maintenance chemotherapy extends the overall survival beyond a year. Recurrence is, however, inevitable. GBM holds several unique features including its vast intratumoral heterogeneity, immunosuppressive environment, and a partially permissive anatomic blood\u2013brain barrier, which offers a unique opportunity to investigate new treatment approaches. Tremendous efforts have been made in recent years to investigate novel CAR targets and target combinations with standard modalities for solid tumors and GBM to improve treatment efficacy. In this review, we outline the history of CAR immunotherapy development, relevant CAR target antigens validated with CAR T cells as well as preclinical approaches in combination with adjunct approaches via checkpoint inhibition, bispecific antibodies, and second-line systemic therapies that enhance anticancer efficacy of the CAR-based cancer immunotherapy.<\/jats:p>","DOI":"10.1007\/s12026-021-09236-x","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T06:28:59Z","timestamp":1632378539000},"page":"471-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5516-9431","authenticated-orcid":false,"given":"Hyeon Joo","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4358-3405","authenticated-orcid":false,"given":"Biyan Nathanael","family":"Harapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"9236_CR1","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319:1676\u201380. https:\/\/doi.org\/10.1056\/NEJM198812223192527.","journal-title":"N Engl J Med"},{"key":"9236_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1098\/rspb.1954.0054","volume":"143","author":"RE Billingham","year":"1954","unstructured":"Billingham RE, Brent L, Medawar PB. Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. Proc R Soc Lond B Biol Sci. 1954;143:58\u201380. https:\/\/doi.org\/10.1098\/rspb.1954.0054.","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"9236_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1084\/jem.102.2.157","volume":"102","author":"NA Mitchison","year":"1955","unstructured":"Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med. 1955;102:157\u201377. https:\/\/doi.org\/10.1084\/jem.102.2.157.","journal-title":"J Exp Med"},{"key":"9236_CR4","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","volume":"76","author":"HJ Kolb","year":"1990","unstructured":"Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462\u20135. https:\/\/doi.org\/10.1182\/blood.V76.12.2462.2462.","journal-title":"Blood"},{"key":"9236_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain M, Rivi\u00e8re I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545:423\u201331. https:\/\/doi.org\/10.1038\/nature22395.","journal-title":"Nature"},{"key":"9236_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imr.12132","volume":"257","author":"CS Hinrichs","year":"2014","unstructured":"Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257:56\u201371. https:\/\/doi.org\/10.1111\/imr.12132.","journal-title":"Immunol Rev"},{"key":"9236_CR7","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","volume":"86","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159\u201366. https:\/\/doi.org\/10.1093\/jnci\/86.15.1159.","journal-title":"J Natl Cancer Inst"},{"key":"9236_CR8","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0116.","journal-title":"Clin Cancer Res"},{"key":"9236_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s0167-5699(96)10075-x","volume":"18","author":"F Garrido","year":"1997","unstructured":"Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997;18:89\u201395. https:\/\/doi.org\/10.1016\/s0167-5699(96)10075-x.","journal-title":"Immunol Today"},{"key":"9236_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJM199008303230904","volume":"323","author":"SA Rosenberg","year":"1990","unstructured":"Rosenberg SA, Aebersold P, Cornetta K, et al. Gene Transfer into humans \u2014 immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323:570\u20138. https:\/\/doi.org\/10.1056\/NEJM199008303230904.","journal-title":"N Engl J Med"},{"key":"9236_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1365-2141.2004.05077.x","volume":"126","author":"M Rischer","year":"2004","unstructured":"Rischer M, Pscherer S, Duwe S, et al. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol. 2004;126:583\u201392. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05077.x.","journal-title":"Br J Haematol"},{"key":"9236_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/jgm.647","volume":"7","author":"F Turatti","year":"2005","unstructured":"Turatti F, Figini M, Alberti P, et al. Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. J Gene Med. 2005;7:158\u201370. https:\/\/doi.org\/10.1002\/jgm.647.","journal-title":"J Gene Med"},{"key":"9236_CR13","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17:1453\u201364. https:\/\/doi.org\/10.1038\/mt.2009.83.","journal-title":"Mol Ther"},{"key":"9236_CR14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12026-008-8057-6","volume":"42","author":"A Varela-Rohena","year":"2008","unstructured":"Varela-Rohena A, Carpenito C, Perez EE, et al. Genetic engineering of T cells for adoptive immunotherapy. Immunol Res. 2008;42:166\u201381. https:\/\/doi.org\/10.1007\/s12026-008-8057-6.","journal-title":"Immunol Res"},{"key":"9236_CR15","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1158\/0008-5472.can-03-2780","volume":"64","author":"H Gyobu","year":"2004","unstructured":"Gyobu H, Tsuji T, Suzuki Y, et al. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res. 2004;64:1490\u20135. https:\/\/doi.org\/10.1158\/0008-5472.can-03-2780.","journal-title":"Cancer Res"},{"key":"9236_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.272.5259.263","volume":"272","author":"L Naldini","year":"1996","unstructured":"Naldini L, Bl\u00f6mer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263\u20137. https:\/\/doi.org\/10.1126\/science.272.5259.263.","journal-title":"Science"},{"key":"9236_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.mt.6300104","volume":"15","author":"JR Park","year":"2007","unstructured":"Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15:825\u201333. https:\/\/doi.org\/10.1038\/sj.mt.6300104.","journal-title":"Mol Ther"},{"key":"9236_CR18","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","volume":"112","author":"BG Till","year":"2008","unstructured":"Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261\u201371. https:\/\/doi.org\/10.1182\/blood-2007-12-128843.","journal-title":"Blood"},{"key":"9236_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1525-0016(03)00099-6","volume":"8","author":"AM Geurts","year":"2003","unstructured":"Geurts AM, Yang Y, Clark KJ, et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther. 2003;8:108\u201317. https:\/\/doi.org\/10.1016\/S1525-0016(03)00099-6.","journal-title":"Mol Ther"},{"key":"9236_CR20","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/sj.mt.6300404","volume":"16","author":"X Huang","year":"2008","unstructured":"Huang X, Guo H, Kang J, et al. Sleeping beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther. 2008;16:580\u20139. https:\/\/doi.org\/10.1038\/sj.mt.6300404.","journal-title":"Mol Ther"},{"key":"9236_CR21","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1158\/0008-5472.CAN-07-5600","volume":"68","author":"H Singh","year":"2008","unstructured":"Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the sleeping beauty system. Cancer Res. 2008;68:2961\u201371. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5600.","journal-title":"Cancer Res"},{"key":"9236_CR22","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1182\/blood-2009-03-210005","volume":"114","author":"X Xue","year":"2009","unstructured":"Xue X, Huang X, Nodland SE, et al. Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood. 2009;114:1319\u201330. https:\/\/doi.org\/10.1182\/blood-2009-03-210005.","journal-title":"Blood"},{"key":"9236_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1089\/hum.2009.114","volume":"21","author":"PVR Manuri","year":"2010","unstructured":"Manuri PVR, Wilson MH, Maiti SN, et al. piggyBac transposon\/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010;21:427\u201337. https:\/\/doi.org\/10.1089\/hum.2009.114.","journal-title":"Hum Gene Ther"},{"key":"9236_CR24","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/CJI.0b013e3181ad762b","volume":"32","author":"Y Nakazawa","year":"2009","unstructured":"Nakazawa Y, Huye LE, Dotti G, et al. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother. 2009;32:826\u201336. https:\/\/doi.org\/10.1097\/CJI.0b013e3181ad762b.","journal-title":"J Immunother"},{"key":"9236_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0065-2660(05)54009-4","volume":"54","author":"PB Hackett","year":"2005","unstructured":"Hackett PB, Ekker SC, Largaespada DA, et al. Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet. 2005;54:189\u2013232. https:\/\/doi.org\/10.1016\/S0065-2660(05)54009-4.","journal-title":"Adv Genet"},{"key":"9236_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/s0092-8674(00)80436-5","volume":"91","author":"Z Ivics","year":"1997","unstructured":"Ivics Z, Hackett PB, Plasterk RH, et al. Molecular reconstruction of sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997;91:501\u201310. https:\/\/doi.org\/10.1016\/s0092-8674(00)80436-5.","journal-title":"Cell"},{"key":"9236_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2217\/14796694.2.3.345","volume":"2","author":"R Frommolt","year":"2006","unstructured":"Frommolt R, Rohrbach F, Theobald M. Sleeping beauty transposon system\u2013future trend in T-cell-based gene therapies? Future Oncol. 2006;2:345\u20139. https:\/\/doi.org\/10.2217\/14796694.2.3.345.","journal-title":"Future Oncol"},{"key":"9236_CR28","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1093\/nar\/gkl301","volume":"34","author":"AM Geurts","year":"2006","unstructured":"Geurts AM, Hackett CS, Bell JB, et al. Structure-based prediction of insertion-site preferences of transposons into chromosomes. Nucleic Acids Res. 2006;34:2803\u201311. https:\/\/doi.org\/10.1093\/nar\/gkl301.","journal-title":"Nucleic Acids Res"},{"key":"9236_CR29","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.exphem.2006.05.023","volume":"34","author":"RP Hollis","year":"2006","unstructured":"Hollis RP, Nightingale SJ, Wang X, et al. Stable gene transfer to human CD34(+) hematopoietic cells using the sleeping beauty transposon. Exp Hematol. 2006;34:1333\u201343. https:\/\/doi.org\/10.1016\/j.exphem.2006.05.023.","journal-title":"Exp Hematol"},{"key":"9236_CR30","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1634\/stemcells.2007-0026","volume":"25","author":"A Wilber","year":"2007","unstructured":"Wilber A, Linehan JL, Tian X, et al. Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells. 2007;25:2919\u201327. https:\/\/doi.org\/10.1634\/stemcells.2007-0026.","journal-title":"Stem Cells"},{"key":"9236_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ymeth.2009.07.001","volume":"49","author":"Z Izsv\u00e1k","year":"2009","unstructured":"Izsv\u00e1k Z, Chuah MK, VandenDriessche T, et al. Efficient stable gene transfer into human cells by the sleeping beauty transposon vectors. Methods. 2009;49:287\u201397. https:\/\/doi.org\/10.1016\/j.ymeth.2009.07.001.","journal-title":"Methods"},{"key":"9236_CR32","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.leukres.2008.11.024","volume":"33","author":"L Boissel","year":"2009","unstructured":"Boissel L, Betancur M, Wels WS, et al. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res. 2009;33:1255\u20139. https:\/\/doi.org\/10.1016\/j.leukres.2008.11.024.","journal-title":"Leuk Res"},{"key":"9236_CR33","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10544-010-9440-3","volume":"12","author":"Y Choi","year":"2010","unstructured":"Choi Y, Yuen C, Maiti SN, et al. A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices. 2010;12:855\u201363. https:\/\/doi.org\/10.1007\/s10544-010-9440-3.","journal-title":"Biomed Microdevices"},{"key":"9236_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169.","journal-title":"N Engl J Med"},{"key":"9236_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","volume":"21","author":"M Sadelain","year":"2009","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21:215\u201323. https:\/\/doi.org\/10.1016\/j.coi.2009.02.009.","journal-title":"Curr Opin Immunol"},{"key":"9236_CR36","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/nm1676","volume":"13","author":"MT Stephan","year":"2007","unstructured":"Stephan MT, Ponomarev V, Brentjens RJ, et al. T cell-encoded CD80 and 4\u20131BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13:1440\u20139. https:\/\/doi.org\/10.1038\/nm1676.","journal-title":"Nat Med"},{"key":"9236_CR37","doi-asserted-by":"publisher","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4:132ra53. https:\/\/doi.org\/10.1126\/scitranslmed.3003761.","journal-title":"Sci Transl Med"},{"key":"9236_CR38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/86280","volume":"2","author":"AM Silverstein","year":"2001","unstructured":"Silverstein AM. Autoimmunity versus horror autotoxicus: the struggle for recognition. Nat Immunol. 2001;2:279\u201381. https:\/\/doi.org\/10.1038\/86280.","journal-title":"Nat Immunol"},{"key":"9236_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/2051-1426-2-14","volume":"2","author":"RR Raval","year":"2014","unstructured":"Raval RR, Sharabi AB, Walker AJ, et al. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2014;2:14. https:\/\/doi.org\/10.1186\/2051-1426-2-14.","journal-title":"J Immunother Cancer"},{"key":"9236_CR40","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","volume":"23","author":"CH June","year":"2017","unstructured":"June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy? Nat Med. 2017;23:540\u20137. https:\/\/doi.org\/10.1038\/nm.4321.","journal-title":"Nat Med"},{"key":"9236_CR41","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.tibtech.2011.04.009","volume":"29","author":"TS Park","year":"2011","unstructured":"Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011;29:550\u20137. https:\/\/doi.org\/10.1016\/j.tibtech.2011.04.009.","journal-title":"Trends Biotechnol"},{"key":"9236_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/cr.2016.154","volume":"27","author":"LA Johnson","year":"2017","unstructured":"Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 2017;27:38\u201358. https:\/\/doi.org\/10.1038\/cr.2016.154.","journal-title":"Cell Res"},{"key":"9236_CR43","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/2326-6066.CIR-15-0048","volume":"3","author":"AJ Davenport","year":"2015","unstructured":"Davenport AJ, Jenkins MR, Cross RS, et al. CAR-T Cells inflict sequential killing of multiple tumor target cells. Cancer Immunol Res. 2015;3:483. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0048.","journal-title":"Cancer Immunol Res"},{"key":"9236_CR44","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","volume":"13","author":"HJ Jackson","year":"2016","unstructured":"Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13:370\u201383. https:\/\/doi.org\/10.1038\/nrclinonc.2016.36.","journal-title":"Nat Rev Clin Oncol"},{"key":"9236_CR45","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1172\/JCI80010","volume":"125","author":"M Sadelain","year":"2015","unstructured":"Sadelain M. CAR therapy: the CD19 paradigm. J Clin Invest. 2015;125:3392\u2013400. https:\/\/doi.org\/10.1172\/JCI80010.","journal-title":"J Clin Invest"},{"key":"9236_CR46","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/0006-291x(87)90502-x","volume":"149","author":"Y Kuwana","year":"1987","unstructured":"Kuwana Y, Asakura Y, Utsunomiya N, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149:960\u20138. https:\/\/doi.org\/10.1016\/0006-291x(87)90502-x.","journal-title":"Biochem Biophys Res Commun"},{"key":"9236_CR47","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86:10024\u20138. https:\/\/doi.org\/10.1073\/pnas.86.24.10024.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9236_CR48","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720\u20134. https:\/\/doi.org\/10.1073\/pnas.90.2.720.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9236_CR49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor. Nat Biotechnol. 2002;20:70\u20135. https:\/\/doi.org\/10.1038\/nbt0102-70.","journal-title":"Nat Biotechnol"},{"key":"9236_CR50","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1182\/blood-2010-01-043737","volume":"116","author":"B Jena","year":"2010","unstructured":"Jena B, Dotti G, Cooper LJN. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010;116:1035\u201344. https:\/\/doi.org\/10.1182\/blood-2010-01-043737.","journal-title":"Blood"},{"key":"9236_CR51","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.4049\/jimmunol.179.7.4910","volume":"179","author":"H Zhang","year":"2007","unstructured":"Zhang H, Snyder KM, Suhoski MM, et al. 4\u20131BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol. 2007;179:4910\u20138. https:\/\/doi.org\/10.4049\/jimmunol.179.7.4910.","journal-title":"J Immunol"},{"key":"9236_CR52","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.4049\/jimmunol.181.4.2855","volume":"181","author":"TN Golovina","year":"2008","unstructured":"Golovina TN, Mikheeva T, Suhoski MM, et al. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol. 2008;181:2855\u201368. https:\/\/doi.org\/10.4049\/jimmunol.181.4.2855.","journal-title":"J Immunol"},{"issue":"1","key":"9236_CR53","doi-asserted-by":"publisher","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","volume":"3","author":"S Guedan","year":"2018","unstructured":"Guedan S, Posey AD, Shaw C, et al. Enhancing CAR T cell persistence through ICOS and 4\u20131BB costimulation. JCI Insight. 2018;3(1):e96976. https:\/\/doi.org\/10.1172\/jci.insight.96976.","journal-title":"JCI Insight"},{"key":"9236_CR54","doi-asserted-by":"publisher","first-page":"579","DOI":"10.4161\/cbt.2.5.545","volume":"2","author":"H Zhang","year":"2003","unstructured":"Zhang H, Merchant MS, Chua KS, et al. Tumor expression of 4\u20131BB ligand sustains tumor lytic T cells. Cancer Biol Ther. 2003;2:579\u201386. https:\/\/doi.org\/10.4161\/cbt.2.5.545.","journal-title":"Cancer Biol Ther"},{"key":"9236_CR55","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","volume":"71","author":"D-G Song","year":"2011","unstructured":"Song D-G, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4\u20131BB). Cancer Res. 2011;71:4617\u201327. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0422.","journal-title":"Cancer Res"},{"key":"9236_CR56","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17:147\u201367. https:\/\/doi.org\/10.1038\/s41571-019-0297-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"9236_CR57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2019","unstructured":"Guedan S, Calderon H, Posey AD, JR, , et al. Engineering and Design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2019;12:145\u201356. https:\/\/doi.org\/10.1016\/j.omtm.2018.12.009.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"9236_CR58","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/eji.1830230705","volume":"23","author":"T Brocker","year":"1993","unstructured":"Brocker T, Peter A, Traunecker A, et al. New simplified molecular design for functional T cell receptor. Eur J Immunol. 1993;23:1435\u20139. https:\/\/doi.org\/10.1002\/eji.1830230705.","journal-title":"Eur J Immunol"},{"key":"9236_CR59","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","volume":"28","author":"RD Guest","year":"2005","unstructured":"Guest RD, Hawkins RE, Kirillova N, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005;28:203\u201311. https:\/\/doi.org\/10.1097\/01.cji.0000161397.96582.59.","journal-title":"J Immunother"},{"key":"9236_CR60","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","volume":"180","author":"SE James","year":"2008","unstructured":"James SE, Greenberg PD, Jensen MC, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008;180:7028\u201338. https:\/\/doi.org\/10.4049\/jimmunol.180.10.7028.","journal-title":"J Immunol"},{"key":"9236_CR61","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1253656","volume":"5","author":"N Watanabe","year":"2016","unstructured":"Watanabe N, Bajgain P, Sukumaran S, et al. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016;5: e1253656. https:\/\/doi.org\/10.1080\/2162402X.2016.1253656.","journal-title":"Oncoimmunology"},{"key":"9236_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","volume":"3","author":"M Hudecek","year":"2015","unstructured":"Hudecek M, Sommermeyer D, Kosasih PL, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3:125\u201335. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0127.","journal-title":"Cancer Immunol Res"},{"key":"9236_CR63","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1158\/2326-6066.CIR-17-0207","volume":"6","author":"VYS Oei","year":"2018","unstructured":"Oei VYS, Siernicka M, Graczyk-Jarzynka A, et al. Intrinsic functional potential of NK-cell subsets constrains retargeting driven by chimeric antigen receptors. Cancer Immunol Res. 2018;6:467\u201380. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0207.","journal-title":"Cancer Immunol Res"},{"key":"9236_CR64","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza L, Pegues M, Geldres C, et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 2017;25:2452\u201365. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.013.","journal-title":"Mol Ther"},{"key":"9236_CR65","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","volume":"184","author":"JS Bridgeman","year":"2010","unstructured":"Bridgeman JS, Hawkins RE, Bagley S, et al. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex. J Immunol. 2010;184:6938\u201349. https:\/\/doi.org\/10.4049\/jimmunol.0901766.","journal-title":"J Immunol"},{"key":"9236_CR66","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","volume":"96","author":"T Brocker","year":"2000","unstructured":"Brocker T. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood. 2000;96:1999\u20132001.","journal-title":"Blood"},{"key":"9236_CR67","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","volume":"181","author":"T Brocker","year":"1995","unstructured":"Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181:1653\u20139. https:\/\/doi.org\/10.1084\/jem.181.5.1653.","journal-title":"J Exp Med"},{"key":"9236_CR68","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1183.","journal-title":"Clin Cancer Res"},{"key":"9236_CR69","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264\u201370. https:\/\/doi.org\/10.1038\/nm.1882.","journal-title":"Nat Med"},{"key":"9236_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144787","volume":"10","author":"H Karlsson","year":"2015","unstructured":"Karlsson H, Svensson E, Gigg C, et al. Evaluation of intracellular signaling downstream chimeric antigen receptors. PLoS ONE. 2015;10: e0144787. https:\/\/doi.org\/10.1371\/journal.pone.0144787.","journal-title":"PLoS ONE"},{"key":"9236_CR71","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388\u201398. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0548.","journal-title":"Cancer Discov"},{"key":"9236_CR72","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1084\/jem.188.4.619","volume":"188","author":"A Krause","year":"1998","unstructured":"Krause A, Guo HF, Latouche JB, et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med. 1998;188:619\u201326. https:\/\/doi.org\/10.1084\/jem.188.4.619.","journal-title":"J Exp Med"},{"key":"9236_CR73","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","volume":"119","author":"D-G Song","year":"2012","unstructured":"Song D-G, Ye Q, Poussin M, et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. 2012;119:696\u2013706. https:\/\/doi.org\/10.1182\/blood-2011-03-344275.","journal-title":"Blood"},{"key":"9236_CR74","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1038\/sj.leu.2404366","volume":"20","author":"A Loskog","year":"2006","unstructured":"Loskog A, Giandomenico V, Rossig C, et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia. 2006;20:1819\u201328. https:\/\/doi.org\/10.1038\/sj.leu.2404366.","journal-title":"Leukemia"},{"key":"9236_CR75","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121:1822\u20136. https:\/\/doi.org\/10.1172\/JCI46110.","journal-title":"J Clin Invest"},{"key":"9236_CR76","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","volume":"12","author":"MA Pul\u00e8","year":"2005","unstructured":"Pul\u00e8 MA, Straathof KC, Dotti G, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12:933\u201341. https:\/\/doi.org\/10.1016\/j.ymthe.2005.04.016.","journal-title":"Mol Ther"},{"key":"9236_CR77","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1103849.","journal-title":"N Engl J Med"},{"key":"9236_CR78","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, et al. 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581\u201390. https:\/\/doi.org\/10.1038\/nm.3838.","journal-title":"Nat Med"},{"key":"9236_CR79","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","volume":"257","author":"G Dotti","year":"2014","unstructured":"Dotti G, Gottschalk S, Savoldo B, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257:107\u201326. https:\/\/doi.org\/10.1111\/imr.12131.","journal-title":"Immunol Rev"},{"key":"9236_CR80","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","volume":"24","author":"G Enblad","year":"2018","unstructured":"Enblad G, Karlsson H, Gammelg\u00e5rd G, et al. A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24:6185\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0426.","journal-title":"Clin Cancer Res"},{"issue":"544","key":"9236_CR81","doi-asserted-by":"publisher","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter AI, Ivey RG, Kennedy JJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 2018;11(544):eaat6753. https:\/\/doi.org\/10.1126\/scisignal.aat6753.","journal-title":"Sci Signal"},{"key":"9236_CR82","unstructured":"U.S. Food & Drug Administration (2017) FDA approves axicabtagene ciloleucel for large B- cell lymphoma"},{"key":"9236_CR83","unstructured":"U.S. Food & Drug Administration (2017) FDA approves tisagenlecleucel for B- cell ALL and tocilizumab for cytokine release syndrome"},{"key":"9236_CR84","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148.","journal-title":"Nat Rev Clin Oncol"},{"key":"9236_CR85","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1709919.","journal-title":"N Engl J Med"},{"key":"9236_CR86","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"9236_CR87","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1708566.","journal-title":"N Engl J Med"},{"key":"9236_CR88","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"9236_CR89","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38. https:\/\/doi.org\/10.1126\/scitranslmed.3005930.","journal-title":"Sci Transl Med"},{"key":"9236_CR90","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1215134.","journal-title":"N Engl J Med"},{"key":"9236_CR91","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/onci.19855","volume":"1","author":"AA Hombach","year":"2012","unstructured":"Hombach AA, Heiders J, Foppe M, et al. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology. 2012;1:458\u201366. https:\/\/doi.org\/10.4161\/onci.19855.","journal-title":"Oncoimmunology"},{"key":"9236_CR92","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","volume":"13","author":"RJ Brentjens","year":"2007","unstructured":"Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13:5426\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0674.","journal-title":"Clin Cancer Res"},{"key":"9236_CR93","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1817226.","journal-title":"N Engl J Med"},{"key":"9236_CR94","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15:31\u201346. https:\/\/doi.org\/10.1038\/nrclinonc.2017.128.","journal-title":"Nat Rev Clin Oncol"},{"key":"9236_CR95","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","volume":"112","author":"TW LeBien","year":"2008","unstructured":"LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008;112:1570\u201380. https:\/\/doi.org\/10.1182\/blood-2008-02-078071.","journal-title":"Blood"},{"key":"9236_CR96","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm827","volume":"9","author":"RJ Brentjens","year":"2003","unstructured":"Brentjens RJ, Latouche J-B, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279\u201386. https:\/\/doi.org\/10.1038\/nm827.","journal-title":"Nat Med"},{"key":"9236_CR97","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso B, Bachier C, Westin J, et al. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433\u201344. https:\/\/doi.org\/10.1200\/EDBK_238691.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"9236_CR98","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, et al. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","journal-title":"Nat Rev Drug Discov"},{"key":"9236_CR99","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122:863\u201371. https:\/\/doi.org\/10.1182\/blood-2013-03-490565.","journal-title":"Blood"},{"key":"9236_CR100","doi-asserted-by":"publisher","first-page":"2386187","DOI":"10.1155\/2018\/2386187","volume":"2018","author":"S Sun","year":"2018","unstructured":"Sun S, Hao H, Yang G, et al. Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies. J Immunol Res. 2018;2018:2386187. https:\/\/doi.org\/10.1155\/2018\/2386187.","journal-title":"J Immunol Res"},{"key":"9236_CR101","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/gt.2010.91","volume":"17","author":"A Hombach","year":"2010","unstructured":"Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc \u201cspacer\u201d domain in the extracellular moiety of chimeric antigen receptors avoids \u201coff-target\u201d activation and unintended initiation of an innate immune response. Gene Ther. 2010;17:1206\u201313. https:\/\/doi.org\/10.1038\/gt.2010.91.","journal-title":"Gene Ther"},{"issue":"14","key":"9236_CR102","doi-asserted-by":"publisher","first-page":"e136012","DOI":"10.1172\/jci.insight.136012","volume":"5","author":"M Castellarin","year":"2020","unstructured":"Castellarin M, Sands C, Da T, et al. A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. JCI Insight. 2020;5(14):e136012. https:\/\/doi.org\/10.1172\/jci.insight.136012.","journal-title":"JCI Insight"},{"key":"9236_CR103","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395. https:\/\/doi.org\/10.1182\/blood-2014-05-552729.","journal-title":"Blood"},{"key":"9236_CR104","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"key":"9236_CR105","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10406-y","author":"BN Harapan","year":"2021","unstructured":"Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol. 2021. https:\/\/doi.org\/10.1007\/s00415-021-10406-y.","journal-title":"J Neurol"},{"key":"9236_CR106","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor t cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"key":"9236_CR107","doi-asserted-by":"publisher","unstructured":"Davila ML, Riviere I, Wang X et al. (2014) Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25. https:\/\/doi.org\/10.1126\/scitranslmed.3008226","DOI":"10.1126\/scitranslmed.3008226"},{"key":"9236_CR108","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18:71\u201384. https:\/\/doi.org\/10.1038\/s41571-020-0427-6.","journal-title":"Nat Rev Clin Oncol"},{"key":"9236_CR109","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6:664\u201379. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0040.","journal-title":"Cancer Discov"},{"key":"9236_CR110","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139. https:\/\/doi.org\/10.1126\/scitranslmed.aac5415.","journal-title":"Sci Transl Med"},{"key":"9236_CR111","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant. 2021;56:552\u201366. https:\/\/doi.org\/10.1038\/s41409-020-01134-4.","journal-title":"Bone Marrow Transplant"},{"key":"9236_CR112","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","volume":"11","author":"EL Siegler","year":"2020","unstructured":"Siegler EL, Kenderian SS. Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies. Front Immunol. 2020;11:1973. https:\/\/doi.org\/10.3389\/fimmu.2020.01973.","journal-title":"Front Immunol"},{"key":"9236_CR113","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(14)71170-2.","journal-title":"Lancet Oncol"},{"key":"9236_CR114","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319.","journal-title":"Cancer Discov"},{"key":"9236_CR115","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi L-A, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404\u201319. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0698.","journal-title":"Cancer Discov"},{"key":"9236_CR116","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han X, Wang Y, Wei J, et al. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J Hematol Oncol. 2019;12:128. https:\/\/doi.org\/10.1186\/s13045-019-0813-7.","journal-title":"J Hematol Oncol"},{"key":"9236_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.32","volume":"2","author":"Z Grada","year":"2013","unstructured":"Grada Z, Hegde M, Byrd T, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2: e105. https:\/\/doi.org\/10.1038\/mtna.2013.32.","journal-title":"Mol Ther Nucleic Acids"},{"key":"9236_CR118","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","volume":"126","author":"M Ruella","year":"2016","unstructured":"Ruella M, Barrett DM, Kenderian SS, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126:3814\u201326. https:\/\/doi.org\/10.1172\/JCI87366.","journal-title":"J Clin Invest"},{"key":"9236_CR119","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J Clin Invest. 2016;126:3036\u201352. https:\/\/doi.org\/10.1172\/JCI83416.","journal-title":"J Clin Invest"},{"key":"9236_CR120","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","volume":"1","author":"E Lanitis","year":"2013","unstructured":"Lanitis E, Poussin M, Klattenhoff AW, et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013;1:43\u201353. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0008.","journal-title":"Cancer Immunol Res"},{"key":"9236_CR121","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31:71\u20135. https:\/\/doi.org\/10.1038\/nbt.2459.","journal-title":"Nat Biotechnol"},{"key":"9236_CR122","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Rupp LJ, Morsut L, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164:770\u20139. https:\/\/doi.org\/10.1016\/j.cell.2016.01.011.","journal-title":"Cell"},{"key":"9236_CR123","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJC, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28:415\u201328. https:\/\/doi.org\/10.1016\/j.ccell.2015.09.004.","journal-title":"Cancer Cell"},{"key":"9236_CR124","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/mt.2015.4","volume":"23","author":"KJ Curran","year":"2015","unstructured":"Curran KJ, Seinstra BA, Nikhamin Y, et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015;23:769\u201378. https:\/\/doi.org\/10.1038\/mt.2015.4.","journal-title":"Mol Ther"},{"key":"9236_CR125","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","volume":"350","author":"C-Y Wu","year":"2015","unstructured":"Wu C-Y, Roybal KT, Puchner EM, et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350:aab4077. https:\/\/doi.org\/10.1126\/science.aab4077.","journal-title":"Science"},{"key":"9236_CR126","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-11-3890","volume":"72","author":"K Urbanska","year":"2012","unstructured":"Urbanska K, Lanitis E, Poussin M, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012;72:1844\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3890.","journal-title":"Cancer Res"},{"key":"9236_CR127","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1073\/pnas.1524155113","volume":"113","author":"DT Rodgers","year":"2016","unstructured":"Rodgers DT, Mazagova M, Hampton EN, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A. 2016;113:E459\u201368. https:\/\/doi.org\/10.1073\/pnas.1524155113.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9236_CR128","doi-asserted-by":"publisher","first-page":"E450","DOI":"10.1073\/pnas.1524193113","volume":"113","author":"JSY Ma","year":"2016","unstructured":"Ma JSY, Kim JY, Kazane SA, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A. 2016;113:E450\u20138. https:\/\/doi.org\/10.1073\/pnas.1524193113.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9236_CR129","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173:1426-1438.e11. https:\/\/doi.org\/10.1016\/j.cell.2018.03.038.","journal-title":"Cell"},{"key":"9236_CR130","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257:83\u201390. https:\/\/doi.org\/10.1111\/imr.12125.","journal-title":"Immunol Rev"},{"key":"9236_CR131","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15:1145\u201354. https:\/\/doi.org\/10.1517\/14712598.2015.1046430.","journal-title":"Expert Opin Biol Ther"},{"key":"9236_CR132","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, Purdon TJ, Koneru M, et al. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7:10541. https:\/\/doi.org\/10.1038\/s41598-017-10940-8.","journal-title":"Sci Rep"},{"key":"9236_CR133","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru M, Purdon TJ, Spriggs D, et al. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4: e994446. https:\/\/doi.org\/10.4161\/2162402X.2014.994446.","journal-title":"Oncoimmunology"},{"key":"9236_CR134","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119:4133\u201341. https:\/\/doi.org\/10.1182\/blood-2011-12-400044.","journal-title":"Blood"},{"key":"9236_CR135","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute G, Prinzing BL, Yi Z, et al. Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants. Cancer Immunol Res. 2017;5:571\u201381. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0376.","journal-title":"Cancer Immunol Res"},{"key":"9236_CR136","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi MP, Yeku O, Li X, et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 2018;23:2130\u201341. https:\/\/doi.org\/10.1016\/j.celrep.2018.04.051.","journal-title":"Cell Rep"},{"key":"9236_CR137","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu B, Ren J, Luo Y, et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 2017;20:3025\u201333. https:\/\/doi.org\/10.1016\/j.celrep.2017.09.002.","journal-title":"Cell Rep"},{"key":"9236_CR138","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1182\/blood-2009-09-241398","volume":"115","author":"JC Markley","year":"2010","unstructured":"Markley JC, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood. 2010;115:3508\u201319. https:\/\/doi.org\/10.1182\/blood-2009-09-241398.","journal-title":"Blood"},{"key":"9236_CR139","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1073\/pnas.0307298101","volume":"101","author":"CA Klebanoff","year":"2004","unstructured":"Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A. 2004;101:1969\u201374. https:\/\/doi.org\/10.1073\/pnas.0307298101.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9236_CR140","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123:3750\u20139. https:\/\/doi.org\/10.1182\/blood-2014-01-552174.","journal-title":"Blood"},{"key":"9236_CR141","doi-asserted-by":"publisher","first-page":"228ra37","DOI":"10.1126\/scitranslmed.3007240","volume":"6","author":"B Mlecnik","year":"2014","unstructured":"Mlecnik B, Bindea G, Angell HK, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med. 2014;6:228ra37. https:\/\/doi.org\/10.1126\/scitranslmed.3007240.","journal-title":"Sci Transl Med"},{"key":"9236_CR142","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA, et al. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71:5697\u2013706. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0103.","journal-title":"Cancer Res"},{"key":"9236_CR143","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/CJI.0b013e31825898e8","volume":"35","author":"L Zhang","year":"2012","unstructured":"Zhang L, Feldman SA, Zheng Z, et al. Evaluation of \u03b3-retroviral vectors that mediate the inducible expression of IL-12 for clinical application. J Immunother. 2012;35:430\u20139. https:\/\/doi.org\/10.1097\/CJI.0b013e31825898e8.","journal-title":"J Immunother"},{"key":"9236_CR144","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","volume":"21","author":"L Zhang","year":"2015","unstructured":"Zhang L, Morgan RA, Beane JD, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res. 2015;21:2278\u201388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2085.","journal-title":"Clin Cancer Res"},{"key":"9236_CR145","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov VD, Themeli M, Sadelain M. PD-1\u2013 and CTLA-4\u2013based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5:215ra172. https:\/\/doi.org\/10.1126\/scitranslmed.3006597.","journal-title":"Sci Transl Med"},{"key":"9236_CR146","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","volume":"18","author":"S Yu","year":"2019","unstructured":"Yu S, Yi M, Qin S, et al. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019;18:125. https:\/\/doi.org\/10.1186\/s12943-019-1057-4.","journal-title":"Mol Cancer"},{"key":"9236_CR147","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.3389\/fimmu.2019.02683","volume":"10","author":"MC Burger","year":"2019","unstructured":"Burger MC, Zhang C, Harter PN, et al. CAR-Engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy. Front Immunol. 2019;10:2683. https:\/\/doi.org\/10.3389\/fimmu.2019.02683.","journal-title":"Front Immunol"},{"key":"9236_CR148","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fphar.2015.00021","volume":"6","author":"W Glienke","year":"2015","unstructured":"Glienke W, Esser R, Priesner C, et al. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. 2015;6:21. https:\/\/doi.org\/10.3389\/fphar.2015.00021.","journal-title":"Front Pharmacol"},{"key":"9236_CR149","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.3389\/fimmu.2020.01965","volume":"11","author":"MA Morgan","year":"2020","unstructured":"Morgan MA, B\u00fcning H, Sauer M, et al. Use of cell and genome modification technologies to generate improved \u201coff-the-shelf\u201d CAR T and CAR NK cells. Front Immunol. 2020;11:1965. https:\/\/doi.org\/10.3389\/fimmu.2020.01965.","journal-title":"Front Immunol"},{"key":"9236_CR150","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","volume":"15","author":"S Ma","year":"2019","unstructured":"Ma S, Li X, Wang X, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15:2548\u201360. https:\/\/doi.org\/10.7150\/ijbs.34213.","journal-title":"Int J Biol Sci"},{"key":"9236_CR151","doi-asserted-by":"publisher","first-page":"34341","DOI":"10.18632\/oncotarget.9114","volume":"7","author":"ER Suarez","year":"2016","unstructured":"Suarez ER, Chang DK, Sun J, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7:34341\u201355. https:\/\/doi.org\/10.18632\/oncotarget.9114.","journal-title":"Oncotarget"},{"key":"9236_CR152","doi-asserted-by":"publisher","first-page":"64607","DOI":"10.18632\/oncotarget.19929","volume":"8","author":"X Zhu","year":"2017","unstructured":"Zhu X, Cai H, Zhao L, et al. CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget. 2017;8:64607\u201321. https:\/\/doi.org\/10.18632\/oncotarget.19929.","journal-title":"Oncotarget"},{"key":"9236_CR153","doi-asserted-by":"publisher","first-page":"108584","DOI":"10.18632\/oncotarget.21017","volume":"8","author":"N Mitwasi","year":"2017","unstructured":"Mitwasi N, Feldmann A, Bergmann R, et al. Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells. Oncotarget. 2017;8:108584\u2013603. https:\/\/doi.org\/10.18632\/oncotarget.21017.","journal-title":"Oncotarget"},{"key":"9236_CR154","doi-asserted-by":"publisher","first-page":"31368","DOI":"10.18632\/oncotarget.15572","volume":"8","author":"A Feldmann","year":"2017","unstructured":"Feldmann A, Arndt C, Bergmann R, et al. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology \u201cUniCAR.\u201d Oncotarget. 2017;8:31368\u201385. https:\/\/doi.org\/10.18632\/oncotarget.15572.","journal-title":"Oncotarget"},{"key":"9236_CR155","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41408-018-0113-4","volume":"8","author":"LR Loureiro","year":"2018","unstructured":"Loureiro LR, Feldmann A, Bergmann R, et al. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells. Blood Cancer J. 2018;8:81. https:\/\/doi.org\/10.1038\/s41408-018-0113-4.","journal-title":"Blood Cancer J"},{"key":"9236_CR156","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843\u201351. https:\/\/doi.org\/10.1038\/mt.2010.24.","journal-title":"Mol Ther"},{"key":"9236_CR157","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","volume":"6","author":"SA Richman","year":"2018","unstructured":"Richman SA, Nunez-Cruz S, Moghimi B, et al. High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunol Res. 2018;6:36\u201346. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0211.","journal-title":"Cancer Immunol Res"},{"key":"9236_CR158","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1158\/2326-6066.CIR-16-0362","volume":"6","author":"MS Magee","year":"2018","unstructured":"Magee MS, Abraham TS, Baybutt TR, et al. Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases. Cancer Immunol Res. 2018;6:509\u201316. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0362.","journal-title":"Cancer Immunol Res"},{"key":"9236_CR159","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3389\/fimmu.2017.01702","volume":"8","author":"E Br\u00e4unlein","year":"2017","unstructured":"Br\u00e4unlein E, Krackhardt AM. Identification and characterization of neoantigens as well as respective immune responses in cancer patients. Front Immunol. 2017;8:1702. https:\/\/doi.org\/10.3389\/fimmu.2017.01702.","journal-title":"Front Immunol"},{"key":"9236_CR160","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/ijc.31147","volume":"142","author":"M-L Schubert","year":"2018","unstructured":"Schubert M-L, Hoffmann J-M, Dreger P, et al. Chimeric antigen receptor transduced T cells: tuning up for the next generation. Int J Cancer. 2018;142:1738\u201347. https:\/\/doi.org\/10.1002\/ijc.31147.","journal-title":"Int J Cancer"},{"key":"9236_CR161","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346\u201354. https:\/\/doi.org\/10.1038\/nature12626.","journal-title":"Nature"},{"key":"9236_CR162","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00262-007-0343-y","volume":"56","author":"DO Croci","year":"2007","unstructured":"Croci DO, Zacar\u00edas Fluck MF, Rico MJ, et al. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother. 2007;56:1687\u2013700. https:\/\/doi.org\/10.1007\/s00262-007-0343-y.","journal-title":"Cancer Immunol Immunother"},{"key":"9236_CR163","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357\u201362. https:\/\/doi.org\/10.1016\/j.csbj.2016.09.003.","journal-title":"Comput Struct Biotechnol J"},{"key":"9236_CR164","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1020.","journal-title":"Cancer Discov"},{"issue":"399","key":"9236_CR165","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O'Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984.","journal-title":"Sci Transl Med"},{"key":"9236_CR166","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4049\/jimmunol.1701155","volume":"200","author":"S Srivastava","year":"2018","unstructured":"Srivastava S, Riddell SR. Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. J Immunol. 2018;200:459\u201368. https:\/\/doi.org\/10.4049\/jimmunol.1701155.","journal-title":"J Immunol"},{"issue":"5","key":"9236_CR167","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/cancers12051075","volume":"12","author":"S Kailayangiri","year":"2020","unstructured":"Kailayangiri S, Altvater B, Wiebel M, et al. Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers. Cancers (Basel). 2020;12(5):1075. https:\/\/doi.org\/10.3390\/cancers12051075.","journal-title":"Cancers (Basel)"},{"key":"9236_CR168","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/0008-5472.CAN-10-2693","volume":"71","author":"V Corbi\u00e8re","year":"2011","unstructured":"Corbi\u00e8re V, Chapiro J, Stroobant V, et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 2011;71:1253\u201362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2693.","journal-title":"Cancer Res"},{"key":"9236_CR169","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40425-017-0274-x","volume":"5","author":"C Tosch","year":"2017","unstructured":"Tosch C, Bastien B, Barraud L, et al. Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC. J Immunother Cancer. 2017;5:70. https:\/\/doi.org\/10.1186\/s40425-017-0274-x.","journal-title":"J Immunother Cancer"},{"key":"9236_CR170","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2:112\u201320. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0170.","journal-title":"Cancer Immunol Res"},{"issue":"14","key":"9236_CR171","doi-asserted-by":"publisher","first-page":"e88328","DOI":"10.1172\/jci.insight.88328","volume":"1","author":"RA Evans","year":"2016","unstructured":"Evans RA, Diamond MS, Rech AJ, et al. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. JCI Insight. 2016;1(14):e88328. https:\/\/doi.org\/10.1172\/jci.insight.88328.","journal-title":"JCI Insight"},{"key":"9236_CR172","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/mt.2014.47","volume":"22","author":"AM Leen","year":"2014","unstructured":"Leen AM, Sukumaran S, Watanabe N, et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014;22:1211\u201320. https:\/\/doi.org\/10.1038\/mt.2014.47.","journal-title":"Mol Ther"},{"key":"9236_CR173","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","volume":"6","author":"A Wing","year":"2018","unstructured":"Wing A, Fajardo CA, Posey AD, JR, , et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol Res. 2018;6:605\u201316. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0314.","journal-title":"Cancer Immunol Res"},{"key":"9236_CR174","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375:2561\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1610497.","journal-title":"N Engl J Med"},{"key":"9236_CR175","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","volume":"5","author":"J Tchou","year":"2017","unstructured":"Tchou J, Zhao Y, Levine BL, et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res. 2017;5:1152\u201361. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0189.","journal-title":"Cancer Immunol Res"},{"key":"9236_CR176","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","volume":"21","author":"SC Katz","year":"2015","unstructured":"Katz SC, Burga RA, McCormack E, et al. Phase I Hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res. 2015;21:3149\u201359. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1421.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"9236_CR177","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/cancers9070092","volume":"9","author":"P Sridhar","year":"2017","unstructured":"Sridhar P, Petrocca F. Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy. Cancers (Basel). 2017;9(7):92. https:\/\/doi.org\/10.3390\/cancers9070092.","journal-title":"Cancers (Basel)"},{"key":"9236_CR178","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559\u201372. https:\/\/doi.org\/10.1038\/nri.2017.49.","journal-title":"Nat Rev Immunol"},{"key":"9236_CR179","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","volume":"33","author":"JA Craddock","year":"2010","unstructured":"Craddock JA, an Lu, Bear A, , et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010;33:780\u20138. https:\/\/doi.org\/10.1097\/CJI.0b013e3181ee6675.","journal-title":"J Immunother"},{"key":"9236_CR180","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon EK, Carpenito C, Sun J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011;17:4719\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0351.","journal-title":"Clin Cancer Res"},{"key":"9236_CR181","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Di Stasi","year":"2009","unstructured":"Di Stasi A, de Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113:6392\u2013402. https:\/\/doi.org\/10.1182\/blood-2009-03-209650.","journal-title":"Blood"},{"key":"9236_CR182","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","volume":"90","author":"AJ Korman","year":"2006","unstructured":"Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297\u2013339. https:\/\/doi.org\/10.1016\/S0065-2776(06)90008-X.","journal-title":"Adv Immunol"},{"key":"9236_CR183","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847\u201356. https:\/\/doi.org\/10.1038\/nbt.4195.","journal-title":"Nat Biotechnol"},{"key":"9236_CR184","doi-asserted-by":"publisher","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","volume":"23","author":"S Li","year":"2017","unstructured":"Li S, Siriwon N, Zhang X, et al. Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors. Clin Cancer Res. 2017;23:6982\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0867.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"9236_CR185","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/ijms19020340","volume":"19","author":"DH Yoon","year":"2018","unstructured":"Yoon DH, Osborn MJ, Tolar J, et al. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-In CAR-T. Int J Mol Sci. 2018;19(2):340. https:\/\/doi.org\/10.3390\/ijms19020340.","journal-title":"Int J Mol Sci"},{"key":"9236_CR186","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu X, Sun Q, Liang X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664. https:\/\/doi.org\/10.3389\/fimmu.2019.02664.","journal-title":"Front Immunol"},{"key":"9236_CR187","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1182\/blood.V130.Suppl_1.4121.4121","volume":"130","author":"EA Chong","year":"2017","unstructured":"Chong EA, Melenhorst JJ, Svoboda J, et al. Phase I\/II study of pembrolizumab for progressive diffuse large B cell lymphoma after anti-CD19 directed chimeric antigen receptor modified T cell therapy. Blood. 2017;130:4121. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.4121.4121.","journal-title":"Blood"},{"issue":"10","key":"9236_CR188","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3390\/ijms20102469","volume":"20","author":"HJ Yoo","year":"2019","unstructured":"Yoo HJ, Liu Y, Wang L, et al. Tumor-specific reactive oxygen species accelerators improve chimeric antigen receptor T cell therapy in B cell malignancies. Int J Mol Sci. 2019;20(10):2469. https:\/\/doi.org\/10.3390\/ijms20102469.","journal-title":"Int J Mol Sci"},{"key":"9236_CR189","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","volume":"127","author":"PA Beavis","year":"2017","unstructured":"Beavis PA, Henderson MA, Giuffrida L, et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017;127:929\u201341. https:\/\/doi.org\/10.1172\/JCI89455.","journal-title":"J Clin Invest"},{"key":"9236_CR190","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2326-6066.CIR-17-0502","volume":"6","author":"N Siriwon","year":"2018","unstructured":"Siriwon N, Kim YJ, Siegler E, et al. CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction. Cancer Immunol Res. 2018;6:812\u201324. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0502.","journal-title":"Cancer Immunol Res"},{"key":"9236_CR191","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed S, Sukumaran S, Bajgain P, et al. Improving chimeric antigen receptor-modified T Cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther. 2017;25:249\u201358. https:\/\/doi.org\/10.1016\/j.ymthe.2016.10.016.","journal-title":"Mol Ther"},{"key":"9236_CR192","doi-asserted-by":"publisher","first-page":"25538","DOI":"10.1074\/jbc.M110.127951","volume":"285","author":"S Wilkie","year":"2010","unstructured":"Wilkie S, Burbridge SE, Chiapero-Stanke L, et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem. 2010;285:25538\u201344. https:\/\/doi.org\/10.1074\/jbc.M110.127951.","journal-title":"J Biol Chem"},{"key":"9236_CR193","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, Lee J, Zhang A, et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26:1855\u201366. https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.003.","journal-title":"Mol Ther"},{"key":"9236_CR194","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3389\/fonc.2019.00322","volume":"9","author":"X Xu","year":"2019","unstructured":"Xu X, Gnanaprakasam JNR, Sherman J, et al. A metabolism toolbox for CAR T therapy. Front Oncol. 2019;9:322. https:\/\/doi.org\/10.3389\/fonc.2019.00322.","journal-title":"Front Oncol"},{"key":"9236_CR195","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","volume":"134","author":"PP Hsu","year":"2008","unstructured":"Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703\u20137. https:\/\/doi.org\/10.1016\/j.cell.2008.08.021.","journal-title":"Cell"},{"key":"9236_CR196","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger R, Rieckmann JC, Wolf T, et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016;167:829-842.e13. https:\/\/doi.org\/10.1016\/j.cell.2016.09.031.","journal-title":"Cell"},{"key":"9236_CR197","doi-asserted-by":"publisher","first-page":"8382","DOI":"10.4049\/jimmunol.181.12.8382","volume":"181","author":"T Ando","year":"2008","unstructured":"Ando T, Mimura K, Johansson CC, et al. Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J Immunol. 2008;181:8382. https:\/\/doi.org\/10.4049\/jimmunol.181.12.8382.","journal-title":"J Immunol"},{"key":"9236_CR198","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","volume":"42","author":"SL Goff","year":"2019","unstructured":"Goff SL, Morgan RA, Yang JC, et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother. 2019;42:126\u201335. https:\/\/doi.org\/10.1097\/CJI.0000000000000260.","journal-title":"J Immunother"},{"key":"9236_CR199","doi-asserted-by":"publisher","unstructured":"Brown CE, Starr R, Aguilar B, et al. Clinical development of IL13R\u03b12-targeting CAR T cells for the treatment of glioblastoma. J Immunother Cancer. 2015;3:P114. https:\/\/doi.org\/10.1186\/2051-1426-3-S2-P114.","DOI":"10.1186\/2051-1426-3-S2-P114"},{"key":"9236_CR200","doi-asserted-by":"publisher","unstructured":"Keu KV, Witney TH, Yaghoubi S, et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med. 2017;9:eaag2196. https:\/\/doi.org\/10.1126\/scitranslmed.aag2196","DOI":"10.1126\/scitranslmed.aag2196"},{"key":"9236_CR201","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, Brawley V, Hegde M, et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3:1094\u2013101. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0184.","journal-title":"JAMA Oncol"},{"key":"9236_CR202","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.15252\/emmm.201302627","volume":"6","author":"SK Carlsson","year":"2014","unstructured":"Carlsson SK, Brothers SP, Wahlestedt C. Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med. 2014;6:1359\u201370. https:\/\/doi.org\/10.15252\/emmm.201302627.","journal-title":"EMBO Mol Med"},{"key":"9236_CR203","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.3171\/2018.2.FOCUS17788","volume":"44","author":"BD Choi","year":"2018","unstructured":"Choi BD, Curry WT, Carter BS, et al. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons. Neurosurg Focus. 2018;44:E13. https:\/\/doi.org\/10.3171\/2018.2.FOCUS17788.","journal-title":"Neurosurg Focus"},{"key":"9236_CR204","doi-asserted-by":"publisher","first-page":"300060520930459","DOI":"10.1177\/0300060520930459","volume":"48","author":"J Liu","year":"2020","unstructured":"Liu J, Shen L, Tang G, et al. Multiple extracranial metastases from glioblastoma multiforme: a case report and literature review. J Int Med Res. 2020;48:300060520930459. https:\/\/doi.org\/10.1177\/0300060520930459.","journal-title":"J Int Med Res"},{"key":"9236_CR205","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/mt.2012.210","volume":"21","author":"KKH Chow","year":"2013","unstructured":"Chow KKH, Naik S, Kakarla S, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013;21:629\u201337. https:\/\/doi.org\/10.1038\/mt.2012.210.","journal-title":"Mol Ther"},{"key":"9236_CR206","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.omtm.2018.01.009","volume":"9","author":"Z Yi","year":"2018","unstructured":"Yi Z, Prinzing BL, Cao F, et al. Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma. Mol Ther Methods Clin Dev. 2018;9:70\u201380. https:\/\/doi.org\/10.1016\/j.omtm.2018.01.009.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"9236_CR207","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/neuonc\/nox116","volume":"20","author":"L Jin","year":"2018","unstructured":"Jin L, Ge H, Long Y, et al. CD70, a novel target of CAR T-cell therapy for gliomas. Neuro Oncol. 2018;20:55\u201365. https:\/\/doi.org\/10.1093\/neuonc\/nox116.","journal-title":"Neuro Oncol"},{"key":"9236_CR208","doi-asserted-by":"publisher","first-page":"171","DOI":"10.18632\/oncotarget.2767","volume":"6","author":"X Zhu","year":"2015","unstructured":"Zhu X, Prasad S, Gaedicke S, et al. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget. 2015;6:171\u201384. https:\/\/doi.org\/10.18632\/oncotarget.2767.","journal-title":"Oncotarget"},{"key":"9236_CR209","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.stem.2020.04.008","volume":"26","author":"P Vora","year":"2020","unstructured":"Vora P, Venugopal C, Salim SK, et al. The rational development of CD133-targeting immunotherapies for glioblastoma. Cell Stem Cell. 2020;26:832-844.e6. https:\/\/doi.org\/10.1016\/j.stem.2020.04.008.","journal-title":"Cell Stem Cell"},{"issue":"430","key":"9236_CR210","doi-asserted-by":"publisher","first-page":"eaao2731","DOI":"10.1126\/scitranslmed.aao2731","volume":"10","author":"S Pellegatta","year":"2018","unstructured":"Pellegatta S, Savoldo B, Di Ianni N, et al. Constitutive and TNF\u03b1-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Sci Transl Med. 2018;10(430):eaao2731. https:\/\/doi.org\/10.1126\/scitranslmed.aao2731.","journal-title":"Sci Transl Med"},{"key":"9236_CR211","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1158\/1078-0432.CCR-13-2218","volume":"20","author":"C Geldres","year":"2014","unstructured":"Geldres C, Savoldo B, Hoyos V, et al. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res. 2014;20:962\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2218.","journal-title":"Clin Cancer Res"},{"key":"9236_CR212","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","volume":"14","author":"X Tang","year":"2019","unstructured":"Tang X, Zhao S, Zhang Y, et al. B7\u2013H3 as a novel CAR-T therapeutic target for glioblastoma. Mol Ther Oncolytics. 2019;14:279\u201387. https:\/\/doi.org\/10.1016\/j.omto.2019.07.002.","journal-title":"Mol Ther Oncolytics"},{"key":"9236_CR213","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","volume":"47","author":"D Nehama","year":"2019","unstructured":"Nehama D, Di Ianni N, Musio S, et al. B7\u2013H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine. 2019;47:33\u201343. https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.030.","journal-title":"EBioMedicine"},{"key":"9236_CR214","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/2326-6066.CIR-15-0060","volume":"4","author":"S Shiina","year":"2016","unstructured":"Shiina S, Ohno M, Ohka F, et al. CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains. Cancer Immunol Res. 2016;4:259\u201368. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0060.","journal-title":"Cancer Immunol Res"},{"key":"9236_CR215","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1378843","volume":"7","author":"P Bocca","year":"2017","unstructured":"Bocca P, Di Carlo E, Caruana I, et al. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model. Oncoimmunology. 2017;7: e1378843. https:\/\/doi.org\/10.1080\/2162402X.2017.1378843.","journal-title":"Oncoimmunology"},{"key":"9236_CR216","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605\u201322. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.006.","journal-title":"Cancer Cell"},{"key":"9236_CR217","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3389\/fonc.2020.01582","volume":"10","author":"JD Patterson","year":"2020","unstructured":"Patterson JD, Henson JC, Breese RO, et al. CAR T cell therapy for pediatric brain tumors. Front Oncol. 2020;10:1582. https:\/\/doi.org\/10.3389\/fonc.2020.01582.","journal-title":"Front Oncol"},{"key":"9236_CR218","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","volume":"26","author":"LK Donovan","year":"2020","unstructured":"Donovan LK, Delaidelli A, Joseph SK, et al. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020;26:720\u201331. https:\/\/doi.org\/10.1038\/s41591-020-0827-2.","journal-title":"Nat Med"},{"issue":"533","key":"9236_CR219","doi-asserted-by":"publisher","first-page":"eaaw2672","DOI":"10.1126\/scitranslmed.aaw2672","volume":"12","author":"D Wang","year":"2020","unstructured":"Wang D, Starr R, Chang W-C, et al. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci Transl Med. 2020;12(533):eaaw2672. https:\/\/doi.org\/10.1126\/scitranslmed.aaw2672.","journal-title":"Sci Transl Med"},{"issue":"2","key":"9236_CR220","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/cells10020265","volume":"10","author":"B Majc","year":"2021","unstructured":"Majc B, Novak M, Jerala NK, et al. Immunotherapy of glioblastoma: current strategies and challenges in tumor model development. Cells. 2021;10(2):265. https:\/\/doi.org\/10.3390\/cells10020265.","journal-title":"Cells"},{"key":"9236_CR221","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.603647","volume":"14","author":"F Di Cintio","year":"2020","unstructured":"Di Cintio F, Dal Bo M, Baboci L, et al. The molecular and microenvironmental landscape of glioblastomas: implications for the novel treatment choices. Front Neurosci. 2020;14: 603647. https:\/\/doi.org\/10.3389\/fnins.2020.603647.","journal-title":"Front Neurosci"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09236-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-021-09236-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09236-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T11:33:02Z","timestamp":1645011182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-021-09236-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":221,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9236"],"URL":"https:\/\/doi.org\/10.1007\/s12026-021-09236-x","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"assertion":[{"value":"22 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}